Study: NCT02889796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg or 100 mg tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg or 100 mg tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg or 100 mg tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg or 100 mg tablet(s) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match filgotinib
Description: Tablet(s) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: 40 mg administered via subcutaneous injection once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Administered via subcutaneous injection once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Administered via subcutaneous injection once every two weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match adalimumab
Description: Administered via subcutaneous injection once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Administered via subcutaneous injection once every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match adalimumab
Description: Administered via subcutaneous injection once every two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Commercially sourced tablet(s) administered orally